Market Overview - Wall Street is experiencing a historic rally, with major indexes closing the first quarter with significant momentum, driven by a breakout in the technology sector and a decline in the CBOE Volatility Index (^VIX) by 17.51% to 25.25, indicating a renewed appetite for risk [1] Major Market Indexes Performance - The Nasdaq Composite (^IXIC) surged 795.99 points, or 3.83%, reaching 21,590.63, led by strong performances in the semiconductor and software sectors [2] - The S&P 500 (^GSPC) gained 184.80 points, or 2.91%, closing at 6,528.52, while the Dow Jones Industrial Average (^DJI) increased by 1,125.37 points, or 2.49%, to 46,341.51 [2] Small-Cap and Fixed-Income Market - Small-cap stocks, represented by the Russell 2000 (^RUT), rose 3.41% to 2,496.37, benefiting from the overall market rally [3] - The 30-year Treasury Yield (^TYX) fell 0.29% to 4.8910, providing breathing room for growth stocks [3] Sector Highlights - The cannabis sector is the top-performing industry, with the AdvisorShares Pure US Cannabis ETF (MSOS) increasing by 13.13% [4] - Biotech stocks are also gaining traction, as the SPDR S&P Biotech ETF (XBI) rose 7.40% [4] - In commodities, Gold Futures (GC=F) surged 3.08% to $4,697.90, while the Junior Gold Miners ETF (GDXJ) increased by 7.09% [4] - The energy sector is facing challenges, with Crude Oil Futures (CL=F) dropping 1.41% to $101.43 per barrel, impacting related ETFs [5] Corporate News - Apellis Pharmaceuticals Inc. (APLS) saw a significant premarket move, with its stock price climbing 136.4% to $40.40 [6] - Centessa Pharmaceuticals plc (CNTA) also posted gains of 45.2% [6] - Major tech companies like Nvidia (NVDA), Apple (AAPL), and Microsoft (MSFT) are trading higher, contributing to the Nasdaq's outperformance [7] Earnings and Upcoming Events - The earnings calendar is active, with McCormick & Company Incorporated (MKC) reporting Q1 results, alongside updates from FactSet Research Systems Inc. (FDS) and TD SYNNEX Corporation (SNX) [8] - Anticipation is high for Nike Inc. (NKE) to report Q3 EPS of $0.29, with other notable companies including PVH Corp. (PVH) and luxury retailer RH (RH) also reporting [9] - Tomorrow, the market will focus on reports from ConAgra Brands Inc. (CAG), MSC Industrial Direct Company Inc. (MSM), and Cal-Maine Foods Inc. (CALM), while monitoring economic data for insights on the Federal Reserve's interest rate decisions [10]

Core Viewpoint - BioAtla, Inc. is implementing a 50-for-1 share consolidation to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00, effective April 6, 2026 [1][2]. Company Actions - The share consolidation will convert every fifty shares of common stock into one share, with no fractional shares issued; stockholders entitled to fractional shares will receive cash equivalent [4]. - The consolidation was approved by stockholders at a special meeting on March 23, 2026, as part of a merger agreement with its wholly-owned subsidiary, BA Merger Sub, Inc. [3]. Impact on Stock and Options - Following the consolidation, the number of shares available under the company's equity incentive plan and employee stock purchase plan will be proportionately reduced, and adjustments will be made to the exercise prices and number of shares for outstanding stock options and warrants [5]. Stockholder Information - Stockholders holding shares electronically will not need to take action to receive post-consolidation shares, while those with shares through brokers will have their positions automatically adjusted [6]. Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with a robust pipeline including ADCs and T cell engagers [7]. - The company has over 780 active patent matters, with more than 500 issued patents, covering its CAB platform technology and products [7]. Clinical Pipeline - BioAtla's clinical pipeline includes Ozuriftamab vedotin (CAB-ROR2-ADC) in Phase 3 for OPSCC and Mecbotamab vedotin (CAB-AXL-ADC) in Phase 2 for multiple solid tumor indications [8][13]. - The company is also developing BA3182, a bispecific T cell engager antibody, currently in Phase 1 for advanced adenocarcinoma [10]. Market Opportunity - Ozuriftamab vedotin targets a market opportunity exceeding $7 billion worldwide, particularly for HPV+ cancers, and has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck [11].

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment but has not demonstrated long-term efficacy as stated by the company [4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion of Anktiva being a cancer vaccine is false, and the Executive Chairman overstated its capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is representing the investors in this class action and has a strong track record in securities fraud litigation, recovering over $916 million for investors in 2025 alone [7].

Core Viewpoint - 10x Genomics is experiencing a positive momentum driven by AI-driven demand and improving execution and profitability trends [1][2]. Group 1: Financial Performance - 10x Genomics reported a fourth-quarter loss of 13 cents per share, which was better than the Wall Street expectation of a 20 cents loss [2]. - Sales for the fourth quarter reached $166.03 million, surpassing the consensus estimate of $159.27 million [2]. - The company forecasts fiscal 2026 sales between $600 million and $625 million, compared to the consensus of $611.58 million [3]. Group 2: AI and Growth Potential - AI-related projects currently represent a small percentage of revenue but are expected to become a significant growth vertical as demand for high-quality biological datasets increases [4]. - The launch of the Spatial Tissue Embedding Learning Atlas (STELA) by Bioptimus, in partnership with 10x Genomics, is seen as a validation of the Xenium spatial transcriptomics platform [5]. - The STELA initiative aims to profile up to 100,000 patient tissue specimens, highlighting the potential for AI-scale spatial data generation [5]. Group 3: Market Activity - 10x Genomics shares increased by 4.49% to $20.70 at the time of publication [5].

Core Insights - The company is transitioning Zippi from an initial build phase to significant scale and margin expansion, with expectations to double annual revenue and achieve EBITDA profitability by late 2026 [1] - Karus is optimizing underwriting models and expanding its customer network, targeting over $50 million in monthly originations by the latter half of 2026 [1] Business Model and Strategy - The company is focused on building an asset supply chain across multiple credit categories, with partnerships and investments in Aero Engine Solutions, Karus, and Zippi [2][3] - The approach combines immediate cash flow generation with long-term scale, relying on real assets generating cash flows rather than Ethereum price speculation [4] Financial Performance - For the fourth quarter, the company reported revenue of approximately $2.4 million, with a full-year revenue of $6.5 million [8] - The net loss for the fourth quarter was approximately $229.7 million, compared to a net loss of $216.7 million in the third quarter, with a full-year net loss of $450.5 million [9] Balance Sheet and Asset Management - As of December 31, 2025, total assets were approximately $306.3 million, with cash and cash equivalents of approximately $8 million [10] - The company has eliminated direct ETH price exposure and currently holds 12,441 ETH as collateral for a loan [11] 2026 Outlook - Initial guidance for year-end 2026 platform assets under management is projected to be between $125 million and $200 million [12] - Full-year 2026 revenue is guided to be between $18 million and $26 million, driven by yield income and structuring fees from tokenized products [13] Future Growth and Capital Deployment - The company plans to deploy its $103 million cash balance into asset purchases and facilities to generate revenue [16] - Targeting year-end 2027 AUM of $300 million to $400 million, which could result in year-over-year revenue growth of 50% to 100% in 2027 [18]

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) for securities fraud, encouraging shareholders to inquire about their rights and potential recovery of losses [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, with a deadline for filing a lead plaintiff motion set for May 26, 2026 [1]. - The lawsuit alleges that the company's Executive Chairman, Patrick Soon-Shiong, made false claims about the lead biologic product, Anktiva, including that it "can cure and even prevent all cancer," which the FDA deemed misleading [3][4]. Group 2: Impact on Shareholders - Following the FDA's warning on March 24, 2026, ImmunityBio's stock price dropped by $1.98, or 21.12%, closing at $7.42 per share, resulting in significant losses for investors [3]. - The complaint asserts that the defendants failed to disclose material adverse facts about the company's business and operations, leading to misleading statements regarding its prospects [4].

Summary of Precigen Conference Call Company Overview - **Company**: Precigen - **Key Product**: Papzimeos, an immunotherapy for recurrent respiratory papillomatosis (RRP) - **Leadership**: Helen Sabzevari (President and CEO), Phil Tennant (Chief Commercial Officer) Core Industry Insights - **FDA Approval**: Papzimeos received FDA approval, marking a significant milestone for Precigen as it transitions into a commercial stage entity [1] - **Market Need**: RRP has historically lacked effective treatments, with patients often undergoing multiple surgeries, leading to severe complications [10][11] - **Patient Demographics**: RRP can affect both children and adults, with severe cases requiring numerous surgeries annually [10][11] Product Details - **Mechanism of Action**: Papzimeos utilizes a unique gorilla adenovirus platform, allowing for a higher capacity of gene presentation (up to 12 KB) and the ability to administer multiple doses without immunogenicity issues [4][5] - **Clinical Efficacy**: In pivotal studies, Papzimeos demonstrated a 51% complete response rate and an 86% overall reduction in surgeries among patients [15][16] - **Safety Profile**: The treatment has shown a favorable safety profile, comparable to receiving a flu shot [61] Commercial Strategy - **Launch Metrics**: The company began dosing patients in November, with a straightforward regimen of four subcutaneous injections over 12 weeks [20][21] - **Market Focus**: Precigen identified approximately 500 hospital systems as key targets for initial commercialization, with a focus on large academic centers and community hospitals [25] - **Patient Engagement**: The company is actively working with patient advocacy groups to raise awareness and ensure patients are informed about treatment options [33][36] Future Plans - **Redosing Studies**: Ongoing studies aim to convert partial responders to complete responders through additional dosing [19][62] - **Pediatric Trials**: Plans to initiate pediatric trials by the end of 2026, expanding the treatment's applicability to younger patients [62] - **Platform Expansion**: Development of PRGN-2009, targeting HPV-related cancers, is underway, leveraging the same adenovirus platform as Papzimeos [64][65] Financial Outlook - **Revenue Projections**: The company anticipates significant revenue growth from Papzimeos, with expectations of reaching break-even by the end of 2026 [82] - **Funding Utilization**: With over $100 million in the bank, Precigen plans to allocate resources towards redosing studies, pediatric trials, and the expansion of PRGN-2009 [84] Key Challenges and Considerations - **Payer Access**: While the company has seen positive payer coverage, some restrictions exist based on prior surgical history [47][49] - **Market Education**: Continuous efforts are needed to educate healthcare providers and patients about RRP and the new treatment options available [36][37] Conclusion Precigen is positioned to make a significant impact in the treatment of RRP with Papzimeos, addressing a long-standing unmet medical need. The company's innovative approach, combined with strategic commercialization efforts and future expansion plans, suggests a promising outlook for both patient outcomes and financial performance.

Market Overview - The US stock market is experiencing a significant surge, driven by optimism that the worst-case energy crisis may be avoided due to changing expectations around the Iran war [1][28] - Major indexes such as the Dow Jones, S&P 500, and Nasdaq have shown substantial gains, with the Nasdaq outperforming other indexes [28] Key Drivers - A notable factor behind the market surge is the potential for de-escalation in the Iran conflict, which previously raised fears of a prolonged oil supply shock [1][28] - Bond markets are supporting equities, with the 10-year Treasury yield dropping below 4.33%, down from around 4.44% last week, making stocks more attractive [5][29] Sector Performance - Technology stocks are leading the rally, benefiting from falling interest rates and improving investor sentiment [6][29] - Biotech and AI sectors are also experiencing strong momentum, with several stocks posting double-digit and even triple-digit percentage gains [9][10] Notable Stock Movements - Apellis Pharmaceuticals surged by 135.66% to $40.27, indicating strong bullish momentum and investor confidence in future growth [10] - Classover Holdings gained 66.83% to $3.42, reflecting renewed speculative interest despite trading far below its 52-week high [11] - Centessa Pharmaceuticals climbed 44.69% to $39.91, showing sustained upward momentum in the biotech sector [12] - Marvell Technology rose 8.40% to $95.18, supported by strong demand in AI infrastructure and strategic partnerships [13] - Nvidia gained 3.31% to $170.64, continuing its leadership in the AI space and contributing significantly to the Nasdaq's strength [14][15] - Tesla advanced 2.60% to $364.51, benefiting from the broader shift toward growth stocks [17] - Micron Technology climbed 1.98% to $328.16, as investors expect stronger demand for memory chips [18] - NIO added 7.53% to $5.92, rebounding as investor sentiment improves toward electric vehicle companies [19] Oil Prices and Inflation - Oil prices remain a critical factor, with crude having surged more than 70% this quarter, but today's mixed movement suggests markets are reassessing the situation [20][22] - Gasoline prices in the U.S. have crossed $4 per gallon for the first time since 2022, highlighting ongoing inflation pressure [21] - The potential stabilization or decline in oil prices could ease inflation fears and support further gains in equities [22]

Core Viewpoint - Applied Digital (APLD) is expected to report its 3Q26 earnings on April 8th, and there is anticipation regarding the insights these earnings will provide into the company's performance and future prospects [1]. Group 1: Company Overview - The company focuses on biotechnology, emphasizing innovation through unique mechanisms of action and first-in-class therapies [1]. - APLD aims to reshape treatment paradigms with its platform technologies, indicating a commitment to advancing the biotech sector [1]. Group 2: Analyst's Approach - The analysis combines scientific expertise with financial and market analysis to deliver research that is both technically sound and investment-driven [1]. - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]. Group 3: Market Engagement - The company plans to engage with investors by providing insights into both opportunities and risks within the biotech sector, highlighting the potential for significant returns through breakthrough science [1]. - There is an emphasis on the importance of careful scrutiny in the biotech industry due to its dynamic and rapidly evolving nature [1].

My vision is that this is, you know, it's a daily beef flavored pill that are given preventatively to keep them healthier longer, similar to a statin, you know, for older Americans. >> And you think it will actually help extend a dog's life. >> Yeah.>> How long. >> Approximately one healthier year of life. Maybe it'll be more, maybe it'll be less.>> One of their drugs in a clinical trial is being given to dogs over the age of 10 who are monitored for signs of aging. The FDA has signed off on the drug safety ...